Novel treatment option Remsima® SC (infliximab) for Crohn’s disease (CD) and Ulcerative Colitis (UC)

Dr Roisin Bevan, Consultant Gastroenterologist and Leung Yu Wu, Directorate Pharmacist discuss the North Tees and Hartlepool NHS Foundation Trust’s experience of switching to Remsima® SC, the benefits and insights gained.

The switching in practice, North Tees and Hartlepool NHS Foundation Trust case study covers multiple aspects of the transition process including:

  • Treatment pathways
  • Choosing between IV and SC administration
  • The switching process
  • Patient engagement with treatment
  • Benefits to both patients and clinic

To read the North Tees and Hartlepool NHS Foundation Trust case study click here.

You can request a hardcopy of this case study by writing to UKinfo@celltrionhc.com

Prescribing information and adverse event reporting details can be found on the back pages of the case study.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Celltrion Healthcare and its authorised commercialisation partners by calling +44 (0)1279 406759 (Diamond Pharma Services)

Summary of product characteristics can be found here https://www.medicines.org.uk/emc/product/11101/smpc#gref

UK-REMS-21-00051 September 2021

Leave a Comment

Scroll to Top